Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

preview_player
Показать описание
Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Dr. Subbiah on 0:01:07

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

Vivek Subbiah, MD, 0:03:00

Vivek Subbiah, MD, on the FDA approved product, selpercatanib, for RET-driven lung & thyroid can...

Data on FDA 0:07:39

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

FDA approval of 0:07:02

FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancers

Dr. Subbiah on 0:01:14

Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors

Dr. Subbiah on 0:02:07

Dr. Subbiah on the Importance of Tivozanib in RCC

Pralsetinib for Advanced 0:58:12

Pralsetinib for Advanced or Metastatic RET-Altered Thyroid Cancer with Dr. Vivek Subbiah

Vivek Subbiah, MD, 0:01:37

Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities to other therapies

‘Mixed Bag’: Only 0:01:10

‘Mixed Bag’: Only a Fraction of Recent Drug Approvals in NSCLC Space ‘Considered Practice Changing’...

Precision Oncology with 0:58:32

Precision Oncology with Dr Vivek Subbiah

Designing clinical trials 0:04:00

Designing clinical trials for precision oncology

Vivek Subbiah, MD, 0:01:54

Vivek Subbiah, MD, on developing targeted therapies for RET fusion + solid tumors and effectivity

Dr. Vivek Subbiah 0:05:00

Dr. Vivek Subbiah discusses the novel lesion selection tool reported in JIPO by Xu et al

Vivek Subbiah, MD, 0:01:30

Vivek Subbiah, MD, describes the incidence of RET-fusion and solid tumors amongst cancer patients

Ishwaria & Vivek 0:32:02

Ishwaria & Vivek Subbiah (Part 1): Origin Story for a Great Oncology Power Couple

Dr. Vivek Subbiah 0:30:05

Dr. Vivek Subbiah on Pioneering Precision Oncology and Global Clinical Trials | OncoInfluencers

How can we 0:18:50

How can we deal with the explosion of new treatments? - FDA

Watch Drs. Drilon, 1:07:25

Watch Drs. Drilon, Demetri, & Subbiah discusss #SolidTumors - https://bit.ly/3PGGxlw

Drs. Subbiah, Beg, 1:40:22

Drs. Subbiah, Beg, Parikh, & Rashid discuss #GICancers at #GI23 - https://bit.ly/3WnYPut

The LAVENDER Trial: 0:05:06

The LAVENDER Trial: Data That Supported the FDA Approval of Trofinetide to Treat Rett Syndrome

Updates in the 0:31:10

Updates in the Management of Thyroid Cancer Virtual Symposium Presentation - Vivek Subbiah, MD

Pralsetinib As A 0:00:56

Pralsetinib As A Potential Agnostic Approach

Next-Generation Sequencing and 0:16:21

Next-Generation Sequencing and Targets in Early-Phase Colorectal Cancer Drug Development

Designing clinical trials 0:46:10

Designing clinical trials for precision oncology. 262